146 related articles for article (PubMed ID: 29498411)
1. RSK1 promotes murine breast cancer growth and metastasis.
Czaplinska D; Gorska M; Mieczkowski K; Peszynska-Sularz G; Zaczek AJ; Romanska HM; Sadej R
Folia Histochem Cytobiol; 2018; 56(1):11-20. PubMed ID: 29498411
[TBL] [Abstract][Full Text] [Related]
2. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
Cuesta R; Holz MK
Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
[TBL] [Abstract][Full Text] [Related]
3. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
Ludwik KA; Campbell JP; Li M; Li Y; Sandusky ZM; Pasic L; Sowder ME; Brenin DR; Pietenpol JA; O'Doherty GA; Lannigan DA
Mol Cancer Ther; 2016 Nov; 15(11):2598-2608. PubMed ID: 27528706
[TBL] [Abstract][Full Text] [Related]
4. p90 ribosomal S6 kinase 1 (RSK1) isoenzyme specifically regulates cytokinesis progression.
Nam HJ; Lee IJ; Jang S; Bae CD; Kwak SJ; Lee JH
Cell Signal; 2014 Feb; 26(2):208-19. PubMed ID: 24269382
[TBL] [Abstract][Full Text] [Related]
5. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
6. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
Guo GC; Wang JX; Han ML; Zhang LP; Li L
Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
[TBL] [Abstract][Full Text] [Related]
7. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Cerqueira OL; Truesdell P; Baldassarre T; Vilella-Arias SA; Watt K; Meens J; Chander H; Osório CA; Soares FA; Reis EM; Craig AW
Oncotarget; 2015 Apr; 6(11):9397-408. PubMed ID: 25823823
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Implications of RSK1-3 in Human Breast Cancer.
Zhao H; Martin TA; Davies EL; Ruge F; Yu H; Zhang Y; Teng XU; Jiang WG
Anticancer Res; 2016 Mar; 36(3):1267-74. PubMed ID: 26977024
[TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
[TBL] [Abstract][Full Text] [Related]
10. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
[TBL] [Abstract][Full Text] [Related]
11. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
12. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
13. miR-629-3p may serve as a novel biomarker and potential therapeutic target for lung metastases of triple-negative breast cancer.
Wang J; Song C; Tang H; Zhang C; Tang J; Li X; Chen B; Xie X
Breast Cancer Res; 2017 Jun; 19(1):72. PubMed ID: 28629464
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
Bouchard G; Therriault H; Geha S; Bérubé-Lauzière Y; Bujold R; Saucier C; Paquette B
BMC Cancer; 2016 Jun; 16():361. PubMed ID: 27282478
[TBL] [Abstract][Full Text] [Related]
15. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
16. An siRNA screen identifies RSK1 as a key modulator of lung cancer metastasis.
Lara R; Mauri FA; Taylor H; Derua R; Shia A; Gray C; Nicols A; Shiner RJ; Schofield E; Bates PA; Waelkens E; Dallman M; Lamb J; Zicha D; Downward J; Seckl MJ; Pardo OE
Oncogene; 2011 Aug; 30(32):3513-21. PubMed ID: 21423205
[TBL] [Abstract][Full Text] [Related]
17. Induction of miRNA-181a by genotoxic treatments promotes chemotherapeutic resistance and metastasis in breast cancer.
Niu J; Xue A; Chi Y; Xue J; Wang W; Zhao Z; Fan M; Yang CH; Shao ZM; Pfeffer LM; Wu J; Wu ZH
Oncogene; 2016 Mar; 35(10):1302-1313. PubMed ID: 26028030
[TBL] [Abstract][Full Text] [Related]
18. Down-regulation of TRAF4 targeting RSK4 inhibits proliferation, invasion and metastasis in breast cancer xenografts.
Zhu L; Zhang S; Huan X; Mei Y; Yang H
Biochem Biophys Res Commun; 2018 Jun; 500(3):810-816. PubMed ID: 29684350
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
20. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]